IRVINE, Calif. -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical" or the "Company"), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced that NEO Skin Clinic Ginza, a clinic to which it provides management support, will begin offering "Skinplus (Cellerdiem)," a next-generation human-derived skin booster, starting Friday, June 19, 2026. The treatment aims to replenish the Extracellular Matrix (ECM), a foundational component of the skin that changes with aging.
In recent years, interest in skin-nurturing treatments has grown, driven by customer needs to improve fundamental skin texture and achieve a natural, youthful appearance. Skinplus is a human-derived skin booster focusing on the ECM, the skin's structural foundation. It has been introduced as a new option expected to address complex skin concerns, including a loss of firmness, elasticity, and enlarged pores.
The primary ingredient in Skinplus is Human Acellular Dermal Matrix (hADM). Unlike conventional approaches to skin treatments that focus primarily on hydration and tissue repair, Skinplus was developed based on the concept of "Matrix Restoration," which targets the ECM. NEO Skin Clinic Ginza currently offers "Re2O (BNAJU)," another hADM-based formulation. While both aim to improve skin quality, they possess different characteristics. By appropriately selecting and utilizing these options based on each customer's skin condition and preferences, the clinic aims to accommodate a broader spectrum of needs.
SBC Medical continuously incorporates advanced global medical insights and promotes the enhancement of knowledge and technical standards through specialized education. In the rapidly evolving field of aesthetic healthcare, the Company pursues safety and reproducibility under a rigorous proprietary verification system, flexibly adopting new treatments based on the latest technology. Moving forward, SBC Medical remains committed to ensuring safety, transparency, and the continuous enhancement of value in line with global standards.
Comment from Dr. Soichiro Morikawa, Director of NEO Skin Clinic Ginza "In my daily consultations, I strongly sense an increasing demand from customers to improve the fundamental condition of their skin. Skinplus, which focuses on the ECM, the foundation of the skin, is expected to be a valuable new option in skin treatments. For these treatments, it is essential to select and combine the appropriate procedures tailored to the customer's concerns, skin condition, and desired outcome. By broadening our treatment options with the introduction of this formulation, we believe we can address a wider range of concerns than ever before. We will continue to prioritize safety and provide treatment proposals closely aligned with each customer."
Notes on the Treatment
・Cellerdiem and Skinplus share identical ingredients and manufacturing processes, differing only in their product names.
・hADM (Human Acellular Dermal Matrix) refers to human skin tissue from which cellular components have been removed, leaving only the ECM components.
・Because this product is formulated with hADM derived from human tissue provided for medical purposes under appropriate consent, individuals who undergo this treatment will not be eligible to donate blood thereafter.
・Treatment suitability and details will be determined by a physician during a consultation.
About SBC Medical Group Holdings Incorporated SBC Medical Group Holdings Incorporated is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose "Contributing to the well-being of people around the world through medical innovation," SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.
Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," "targets" or "hopes" or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at www.sec.gov.
Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Chief Public Relations Officer; E-mail: pr@sbc.or.jp